What Is Tirzepatide? How It Works & Clinic Use
Tirzepatide is a dual GIP/GLP-1 receptor agonist used for blood sugar control and weight loss. Learn what it is, how it works, and how clinics prescribe it.
What Is Tirzepatide?
Tirzepatide is a synthetic peptide that acts on two hormone receptors simultaneously — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). That dual-action mechanism is what sets it apart from older single-agonist drugs in the same class.
The FDA approved tirzepatide in May 2022 under the brand name Mounjaro for type 2 diabetes management. A second approval followed in November 2023 under the brand name Zepbound, specifically for chronic weight management in adults with obesity or weight-related conditions. Both approvals cover the branded, manufacturer-produced injectable formulations.
Compounded versions of tirzepatide are also offered by some clinics, typically through licensed compounding pharmacies. The regulatory status of compounded tirzepatide has shifted — the FDA has periodically updated its guidance on whether tirzepatide remains eligible for compounding, so patients should verify the current legal status with their prescribing physician before starting any compounded version.
How Tirzepatide Works
To understand tirzepatide, it helps to know what GIP and GLP-1 actually do.
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals the pancreas to produce insulin, slows gastric emptying so you feel fuller longer, and acts on the brain's appetite centers to reduce hunger. GLP-1 receptor agonists as a class have been widely studied for both diabetes and weight management.
GIP (glucose-dependent insulinotropic polypeptide) is a related incretin hormone. It also stimulates insulin secretion and may play a role in fat metabolism and energy balance. GIP receptors are found in fat tissue, and activating them appears to complement GLP-1 signaling in meaningful ways.
Tirzepatide is engineered to activate both receptors with a single weekly injection. Clinical trial data published through sources indexed on NIH/PubMed showed participants achieving notably greater reductions in HbA1c and body weight compared to GLP-1-only treatments — though individual outcomes vary considerably.
The practical effects reported in clinical settings include:
- Reduced appetite and caloric intake
- Slower gastric emptying
- Improved insulin sensitivity
- Meaningful reductions in body weight over time
- Lower fasting glucose levels in people with type 2 diabetes
Who Is It Typically Prescribed For?
Physicians consider tirzepatide for two primary populations:
- Adults with type 2 diabetes who need better glycemic control, particularly those who haven't reached target HbA1c levels with other oral or injectable medications.
- Adults with obesity (BMI ≥ 30) or overweight adults (BMI ≥ 27) with at least one weight-related condition such as hypertension, dyslipidemia, or sleep apnea.
Tirzepatide is not approved for type 1 diabetes. It also carries a boxed warning regarding a potential risk of thyroid C-cell tumors observed in animal studies, which is why it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A licensed physician will review your full medical history before prescribing.
How Clinics Use Tirzepatide
Tirzepatide is administered as a subcutaneous (under-the-skin) injection, typically once per week. The branded versions come in prefilled auto-injector pens at several dose strengths.
In clinical practice, most providers follow a dose-escalation protocol — starting low to allow the body to adjust, then gradually increasing over several weeks or months toward a maintenance dose. This approach is designed to minimize common side effects like nausea, vomiting, and diarrhea, which are most pronounced early in treatment.
Clinics that offer tirzepatide — particularly those focused on metabolic health, medical weight loss, or hormone optimization — generally pair it with:
- Nutritional guidance to support sustainable dietary changes
- Regular lab monitoring to track blood glucose, lipid panels, and other metabolic markers
- Follow-up appointments to assess tolerance, adjust dosing, and evaluate progress
- Lifestyle coaching addressing sleep, activity, and stress, which interact with metabolic health
Some clinics position tirzepatide within broader peptide therapy programs alongside agents like semaglutide for patients transitioning between protocols, or combine it with body composition-focused peptides when clinically appropriate.
Branded vs. Compounded Tirzepatide
This distinction matters. Mounjaro and Zepbound are FDA-approved branded drugs manufactured by Eli Lilly with rigorous quality controls. Compounded tirzepatide, prepared by state-licensed compounding pharmacies, has been available during periods of drug shortage but lacks the same FDA pre-market approval process.
The FDA has stated clearly that compounded drugs are not FDA-approved and may carry different risk profiles. If a clinic is offering compounded tirzepatide, ask:
- Is the pharmacy 503A (patient-specific) or 503B (outsourcing facility) licensed?
- What is the current FDA guidance on compounding eligibility for tirzepatide?
- What quality testing does the pharmacy perform?
These are reasonable questions. A reputable clinic will answer them directly.
What to Ask Before Starting
Before committing to a tirzepatide protocol, Mayo Clinic and similar health authorities recommend patients discuss:
- Their full medication list (tirzepatide can affect absorption of oral medications due to gastric slowing)
- Personal or family history of thyroid or pancreatic conditions
- Realistic expectations — tirzepatide supports weight loss and metabolic improvement, but is not a standalone solution
- Long-term plan, including what happens if the medication is discontinued
Tirzepatide is a prescription medication. Any clinic offering it without a physician evaluation, lab work, and proper informed consent should raise immediate concern.
This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any prescription therapy.